1 Wang CY, Wang PN, Chiu MJ, Finstad CL, Lin F, Lynn S, et al. UB-311, a novel UBITh® amyloid β peptide vaccine for mild Alzheimer’s disease. Alzheimer’s & Dementia: Translational Research & Clinical Interventions 3 (2017) 262-272.
2 Chen HC, Wang PN, Chiu MJ, Huang CC, Chang CC, Yen TC, Lin KJ, Seibyl J, Hesterman J, Wang CY, Verma A. (2017, November). Low PET screen failure rate in the UB-311 phase 2A study enriched for ApoE4 carriers with mild cognitive deficit. Poster session presented at Clinical Trials of Alzheimer’s Disease, Boston, MA.
3 Verma A, Maruff P, Schembri A, Wang PN, Chiu MJ, Huang CC, Chang CC, Chen HC, Chang P, Wang CY. (2017, November). UB-311 active vaccine generates titers specific for Aβ oligomers and fibrils without evidence of ARIA-E or encephalopathy in a completed Phase 1 and an ongoing Phase 2a study in Alzheimer’s disease. Poster session presented at Clinical Trials of Alzheimer’s Disease, Boston, MA.
4 Wang, C.Y., Wang, PN, Chiu,.J, Finstad, CL, Lin, F, Lynn, S, Tai, YH, Fang, XD, Zhao, K, Hung, CH, Tseng, Y, Pen, WJ, Wang, J, Yu, CC, Kuo, BS, Frohna, P. UB-311 a novel UBITh® amyloid-β immunotherapeutic vaccine for immunotherapy of mild Alzheimer’s disease. Alzheimer’s & Dementia Translational Research & Clinical Interventions 2017, 3:262-272. Supplementary data related to this article can be can be found at: http://dx.doi.org/10.1016/j.trci.2017.03.005.
5 Wang CY, Wong WW, Tsai HC, Chen YH, Liao MJ, Lynn S. Poster Abstract 450LB: A Phase 2 Open-Label Trial of Antibody UB-421 Monotherapy as a Substitute for HAART. Presented at the Annual Conference on Retroviruses and Opportunistic Infections (CROI), February 13-16, 2017, Seattle, WA.
6 Wang, C.Y. “Peptide Immunogens from the C-Terminal End of Alpha Synuclein Protein and Formulations Thereof for treatment of Synucleinopathies.” US Provision Patent Application No. 62/521,287 (2017).
7 Wang, C.Y. “TAU peptide immunogen constructs. US Patent Application” US Provisional Application 62/578,124 (2017)
8 Wang, C.Y. “Treatment and Sustained Virologic Remission of HIV Infection by Antibodies to CD4 in HAART Stabilized Patients” TW Patent Application 106127443 (2017) and WO Application No. PCT/US2017/046668. (2017)
9 Wang C. Y. et al., “Immunoglobulin fusion proteins and use thereof” US Patent Application 15/002,396 (2016), TW Patent Application 105117815 (2016) and WO Patent Application PCT/US16/039615 (2016).
10 Wang C. Y., “Treatment and functional cure of HIV infection by monoclonal antibodies to CD4 mediating competitive HIV entry inhibition” US Patent Application 15/512,043 (2017).
11 Wang C. Y., and Peng W. J., “Immunogenic LHRH composition and use thereof in pigs” US Patent Application 15/329,154 (2017).
12 Wang C. Y., “Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer’s type” US Patent 9,102,752 (2015), US Patent Application 14/824,075 (2015), and WO Patent Application PCT/US13/37865 (2013).
13 Wang C. Y., “Synthetic peptide-based emergency vaccine against foot and mouth disease (FMD)” US Patent Application 14/443,363 (2015), and WO Patent Application PCT/US2012/065386 (2012).
14 Wang C. Y., “Synthetic Peptide-Based Marker Vaccine and Diagnostic System for Effective Control of Porcine Reproductive and Respiratory Syndrome (PRRS)” US Patent Application 14/380,010 (2014), and WO Patent Application PCT/US/2011/068133 (2011).
15 Wang C. Y. and Peng W. J., “Designer Peptide-based PCV2 Vaccine” WO Patent Application PCT/US/2010/041406 (2010).
16 Wang, Chang Yi, Finstad, Connie L., Walfield, Alan M., Sia Charles, Sokoll, Kenneth K., et al. Site Specific UBITh Amyloid-β Vaccine Amyloid beta for Immunotherapy of Alzheimer's Disease Alzheimer's disease. Vaccine, 2007: 25: 3041-3052.
17 Wang, Chang Yi, Walfield, Alan M. Site-specific peptide vaccines for immunotherapy and immunization against chronic diseases, cancer, infectious diseases, and for veterinary applications. [Review Article] Vaccine 2005: 23:2049-2056.
18 Hseuh PR, Kao CL, Lee CN, Chen LK, Ho MS, Sia C, Fang XD, Lynn S, et al. and Wang, CY. Highly Specific Severe acute respiratory syndrome Antibody Test for Serosurveillance. Emerg. Infect. Diseases 2004, 10:1558-1562
19 Wang, C.Y., Lynn, S., Jong, M-H., Lin, Y-L., et al. Appendix 58, Full protection in pigs against FMDV challenge following single dose of synthetic emergency vaccine. In Report of the Session of the Research Group of the Standing Technical Committee of the European Commission for the Control of Foot-and-Mouth Disease. Food and Agricultural Organization, Rome, pp. 365–375, 2004.
20 Finstad, CL, Wang, CY, Kowalski J, Zhang M, Li ML, Li XM, Xi WG, Bosland MC, Murthy KK, Walfield AM, and Zamb TJ. Synthetic luteinizing Hormone releasing hormone (LHRH) vaccine for effective androgen deprivation and its application to Prostate Cancer immunotheray. Vaccine 2004: 22:1300-1313
21 Wang, CY, Walfield AM, Fang X, Hammerberg B, Ye J, Li ML, Shen F, Shen M, Alexander V and MacGlashan DW. Synthetic IgE peptide vaccine for immunotherapy for Allergy. Vaccine 2003, 21:1580-1590.
22 Wang, CY, Shen M, Tam G, Fang XD, Ye J, Shen F, Walfield AM, Wang JJG, et al. Synthetic AIDS vaccine by targeting HIV receptor. Vaccine 2002, 21: 89-97.
23 Wang, CY, Chang TY, Walfield AM, Ye J, Shen M, Chen SP, Li MC, Lin YL, et al. Effective Synthetic peptide vaccine for Foot and mouth disease in swine. Vaccine. 2002, 20:2603-2610.
24 Wang, CY, Chang TY, Walfield AM, Ye J, Shen M, Zhang ML, Lubroth J, et al. Synthetic Peptide-based Vaccine and Diagnostic System for Effective Control of Foot and mouth disease. Biologicals 2001, 29: 221-228.
25 Wang, CY, Sawyer LSW, Murthy KK, Fang XD, Walfield AM, et al. Postexposure immunoprophylaxis of HIV primary isolates by an antibody to HIV receptor complex. Proc. Natl. Acad. Sci. United States 1999; 96:10367-10372
26 Shen F, Chen PD, Walfield AM, Ye J, House J, Brown F, Wang CY. Differentiation of convalescent animals from those vaccinated against Foot and mouth disease by a peptide ELISA. Vaccine, 1999; 17:3039-3049.
27 Singh M, Li XM, Wang H, McGee JP, Zamb T, Koff W, Wang CY, et al. Controlled release microparticles as a single dose diphtheria toxoid vaccine; immunogenicity in small animal models. Vaccine 1998; 16:346-352.
28 Singh M. Hio C, Qiu H, Li XM, Wang CY, et al. CTL induction using synthetic peptides delivered in emulsions – critical role of the formulation procedure. Vaccine 1997; 15:1773-1778.
29 Li D, Forrest BD, Li Z, Xue P, Hanson CV, Duan S, Cheng H, Li M, Wang CY, et al. International clinical trials of HIV vaccines: II. Phase I trial of an HIV-1 synthetic peptide vaccine evaluating an accelerated immunization schedule in Yunnan, China. Asian Pac J Allergy Immunol 1997; 15: 105-113.
30 Phanuphak P. Teeratakulpixarn S, Sarangbin S, Nookhai S, Ubolyam S, Sirivichayakul S, Leesavan A, Forrest BD, Hanson CV, Li ML, Wang, CY, et al. International clinical trials of HIV vaccines: I. Phase I trial of an HIV-1 synthetic peptide vaccine in Bangkok, Thailand. Asian Pac J Allerg Immunol 1997; 15:41-48.
31 Singh M, McGee JP, Li XM, Koff W, Zamb T, Wang CY and O’Hagan DT. Biodegradable microparticles with an entrapped branched octameric peptide as a controlled-release HIV-1 vaccine. J Pharmaceut Sci 1997; 86:1229.
32 Singh M, Li XM, McGee JP, Zamb T, Koff W, Wang CY and O’Hagan DT. Controlled release microparticles as a single dose hepatitis B vaccine; evaluation of immunogenicity in mice. Vaccine 1997; 15:475.
33 Singh M, Li XM, Wang HY, McGee JP, Zamb T, Koff W, Wang CY and O’Hagan DT. Immunogenicity and protection in small-animal models with controlled-release tetanus toxois microparticles as a single-dose vaccine. Infect and Immunity 1997; 65:1716.
34 Nixon DF, Hioe C, Chen PD, Bian Z, Kuebler P, Li ML, Qiu H, Li XM, Singh M, Richardson J, McGee P, Zamb T, Koff W, Wang CY and O’Hagan D. Syntehtic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine 1996; 14:1523.
35 Hioe CE, Qiu H, Chen PD, Bian Z, Li ML, Li J, Singh M, Kuebler P, McGee P, O’Hagan D, Zamb T, Koff W, Allsopp C, Wang CY, et al. Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides. Vaccine 1996: 14:412-418.
36 Quiroga JA, van Binsbergen J, Wang CY, Pardo M, Navas S, Trines C, Herrero M and Carreno V. Immunoglobulin M antibody to hepatitis C virus core antigen: Correlations with viral replication, histological activity, and Liver disease outcome. Hepatol 1995; 11:1635.
37 Prince AM, Brotman B, Inchauspe G, Pascual D. Nasoff M. Hosein B and Wang CY. Patterns and prevalence of hepatitis type C infection in post-transfusion non-A, non-B hepatitis. J Inf Dis 1993; 167: 1296-1301.
38 Sheu JC, Wang JT, Wang TH, Wang CY, et al. Prevalence of hepatitis C viral infection in a community in Taiwan. Detection by synthetic peptide-based assay and polymerase chain reaction. J Hepatol 1993; 17:192.
39 Wang, CY, Looney, P.J., Li, M.L., Walfield, A.M., Ye, J., Hosein, B., Tam, J.P., and Wong-Staal, F. Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen. Science 1991; 254:285-288
40 Hosein B, Fang X and Wang CY. Anti-HCV, anti-GOR, and autoimmunity. Lancet 1992, 339:871.
41 Hosein B, Fang CT, Popvsky MA, Ye J, Zhang M and Wang, CY. Improved serodiagnosis of hepaptis C virus infection with synthetic peptide antigen from capsid protein. Proc Natl Acad Sci USA. 1991; 88:3647.
42 Hosein B, Present W, Wang CY, and Fang CT. synthetic peptide-based EIAs to distinguish HTLV-I from HTLV-II infection. Transfusion 1990; 30S: 513.
43 Kao HT, Gregerson PK, Tang JC, Takahashi T, Wang CY and Silver J, Molecular analysis of HLA class genes in two DR6w-related haplotypes, DRw13 DQw1 and DRw14 DQw3. J Immunol 1989; 142: 1743.
44 Sung SSJ, Bjorndahl JM, Wang CY, Kao HT and Fu SM. Production of tumor necrosis factor/cachectin by human T cell lines and peripheral blood T lymphocytes stimulated by PMA and Anti-CD3 monoclonal antibody. J Exp Med 1988; 167: 937.
45 Sung SSJ, Jung LKL, Walters JA, Chen W, Wang CY, and Fu SM, Production of tumor necrosis factor/cachectin by human B cell lines and tonsillar B cells. J Exp Med 1988; 168: 1539.
46 Wang CY. Synthetic-peptide-based immunodiagnosis of retrovirus infection: current status and future prospects. In “Synthetic Peptides in Biotechnology.”, Edited by A. Mizrahi, Adv. In Biotechnological Processes. 1988; 10:131.
47 Shimazaki C, Wisniewolski D, Scheinberg D, Atzpodien J, Strife A, Gulati S, Fried J,Wisniewolski R, Wang CY and Clarkson B. Elimination of myeloma cells from bone marrow by using Monoclonal antibodies and magnetic immunobeads. Blood 1988: 72:1248.
48 Gottlieb AB, Lifshitz B, Fu SM, Staiano-Coico L, Wang CY and Carter DM. Expression of HLA-DR molecules by Keratinocytes and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques. J Exp Med 1986; 164: 1013.
49 Gregerson P, Shen M, Song Q, Wang CY, et al. Molecular diversity of HLA-DR4 haplotypes. Proc Natl. Acad Sci USA 1986; 83: 2642. 35.
50 Rinnooy-Kan EA, Wright SD, Welte K and Wang CY. Fc receptors on monocytes cause OKT-3 treated lymphocytes to internalize T3 and secrete IL-2. Cell Immunol 1986; 98: 181.
51 Buskin Y, Posnett DN, Pernis B and Wang CY. A new HLA-linked T cell membrane molecule, related to the beta chain of the clonotypic receptor, is associated with T3. J Exp Med 1986; 164: 458.
52 Posnett D, Wang CY and Friedman SM. Inherited polymorphism of the human T cell antigen receptor detected by a monoclonal antibody. Proc Natl. Acad Sci USA 1986; 83:7888.
53 Tse DB, Al-Haiden M, Pernis B, Cantor CR and Wang CY. Intracellular accumulation of T cell receptor complex molecules in a human T leukemia cell line. Science 1986; 234:748.
54 Wang JG, Steel S, Wisniewolski R and Wang CY. Detection of antibodies to HTLV-III using a synthetic peptide of 21 amino acid residues corresponding to a highly antigenic segment of gp41 envelope protein. Proc Natl Acad Sci USA 1986; 83:6159.
55 Wang CY, Bushin Y, Lane CL, McGrath H and Posnett DN. Stimulation and expansion of a human T cell subpopulation by a monoclonal antibody to T cell receptor molecule. Hybridoma 1986; 5:179.
56 Schwarting R, Stein H and Wang CY. monoclonal antibody S-HCL1, S-HCL3[also termed LEU13 and LEU14] allow the diagnosis of hairy cell leukemia. Blood 1985; 65:974.
57 Bushkin Y, Chorney MJ, Diamante E, Lane CL, Fu SM and Wang, CY. Biochemical characteriazation of a p43,12 complex: comparison to human and murine class I molecules. Mol Immunol 1985; 22:695.
58 Schwarting R, Welte K, Chiorazzi N, Ralph P, Lane CL, Long CW, and Wang, CY. Biochemical characterization and purification of human B cell stimulatory factory (BSF). Eur J Immunol 1985; 15:632.
59 Wang, CY, Bushkin Y, Chen BPD, Platsoucas C and Long CW. Preparation and characterization of monoclonal antibodies directed against epitopes of Human IFN-g. Hybridoma 1984; 4:321.
60 Bushkin Y, Chorney MJ, Diamante E, Fu SM and Wang, CY. Biochemical characterization of the human T6 antigen; a comparison between T6 and murine TL. Mol. Immunol 1984; 21:821.
61 Posnett DN, Biegler RD, Bushkin Y, Fisher DE, Wang, CY, Mayer LF, Chiorazzi N and Kunkel HG. T cell anti-idiotypic antibodies reveal differences between two human leukemias. J Exp Med 1984; 160:499.
62 Posnett DN, Wang, CY, Chiorazzi N, Crow MK and Kunkel HG. An antigen characteristic of hairy cell leukemia cells is expressed on certain activated B cells. J immunol 1984; 133:1635.
63 Peng RL, Al-Katib A, Knowles DM, Lu L, Broxmeyer H, Telidjian B, C Hiao JW and Wang, CY. Preparation and characterization of monoclonal antibodiesrecognizing two distinct differentiation antigens Pro-Im1, Pro-Im2 on early hematopoeitic cells. Blood 1984; 64:1169.
64 Rinnooy Kan EA, Platzer E, Welte K, and Wang, CY. Modulation induction of the T3 antigen by OKT3 is monocyte dependent. J Immunol 1984; 133:2979.
65 Wang, CY, Azzo W, Al-Katib A, Chiorazzi N and Knowles DM. Preparation and characterization of monoclonal antibodies recognizing three distinct differentiation antigens (BL1, BL2, and BL3) on human B lymphocytes. J Immunol 1984; 1133:684.
66 Wang, CY, Al-Katib A, Lane CL, Koziner B and Fu, SM. Induction of Leu 10 (HLA-DC/DS) antigen expression by human precursor B cell lines. J Exp Med 1983; 158:1757.
67 Rinnooy Kan EA, Wang, CY, Wang LC and Evans RL. Non-covalently bonded subunits of 22KD and 28KD are rapidly internalized by T cells reacted with anti-Leu4 [now termed CD3] antibody. J Immunol 1983; 131:536.
68 Biegler RD, Fisher DE, Wang, CY, Rinnooy Kan EA and Kunkel HG. Idiotype-like molecules on cells of a human T-cell leukemia. J Exp Med 1983; 158:1000.
69 Welte K, Platzer EW, Wang, CY, Rinnooy Kan EA, Moore MAS and Mertelsmann R. OKT8 [now termed CD8] antibody inhibits OKT3 [now termed CD3]-induced IL-2 production and proliferation of CD8+ cells. J Immunol 1983; 131:2356.
70 Knowles DM, Tolidgian B, Maiboe CC, Halper J, Azzo W and Wang, CY. A new human B lymphocyte surface antigen (BL2) detected by a monoclonal antibody: Distribution of benign and malignant lymphoid cells. Blood 1983; 62:191.
71 Venuta S, Mertelsmann R, Welte K, Feldman S, Wang, CY and Moore MAS. Production and regulation of Interleukin-2 in human lymphoblastic leukemias studied with T cell monoclonal antibodies. Blood 1983; 61:781.
72 Miki Y, Kishi H, Muragachi A, Maruyama S, Kishimoto S, Yamamura Y, Wang, CY and Kishimoto T. Induction of IgG production in a human monoclonal B lymphoblastoid cell line by a B cell-specific monoclonal antibody (BL2). J Immunol 1982; 1290: 1921.
73 Welte K, Wang, CY, Mertelsmann R, Venuta S, Feldman S and Moore MAS. Purification of human Interleukin-2 to apparent homogeneity and its molecular heterogeneity. J Exp Med 1982; 156:454.
74 Shin HS, Wang, CY and Choi YS. Activation of autologous reactive helpter T lymphocytes for differentiation of human B lymphocytes. J Immunol 1981: 126:2483.
75 Wang, CY, Good RA, Ammirati P, Dymbort G and Evans RL. Identification of a p69/71 complex [now termed LEU 1 or CD5] expressed on human T cells sharing determinants with B type chronic lymphatic leukemia. J Exp Med 1980; 151: 1539.
76 Halper J, Knowles DM and Wang, CY. la antigen expression by human malignant lymphomas: correlation with conventional lymphoid markers. Blood 1980; 55:373.
77 Gottlieb AB, FU SM, YU DTY, Wang, CY, Halper JP and Kunkel HG. The nature of the stimulation cell in human allogeneic and autologous MLC reaction: Role of isolated IgM-bearing B cells. J Immunol 1979; 123: 1497.
78 Wang, CY, Structural and functional characterization of surface antigen on human B lymphocyte. Ph.D. Thesis, The Rockefeller University, 1979.
79 Wang, CY, Fu SM and Kunkel HG. Isolation and immunological characterization of a major surface glycoprotein gp54 preferentially expressed on certain human B cells. J Exp Med 1979; 149:1434.
80 Fu SM, Chiorazzi N, Wang, CY, Montazeri CM and Kunkel HG la bearing T cells in man. Their identification and role in the generation of allogeneic helper activity. J Exp Med 1978; 148:1423.
81 Winchester RJ, Wang, CY, Gibofsky A, Kunkel HG, Lloyd K and Old, LJ. Expression of la-like antigens on cultured human malignant melanoma cell lines. Proc Natl. Acad Sci. 1978; 75:6235.
82 Winchester RJ, Meyers PA, Broxmeyer HE, Wang, CY, Moore MAS and Kunkel HG. Inhibition of human erythropoietic colony formation in culture by treatment with la antisera. J Exp Med 1978; 148:613.
83 Halper JP, Fu SM, Wang, CY, Winchester RJ and Kunkel HG. Patterns of expression of human la-like antigens during the terminal stages of B cell development. J Immunol 1978; 119:1520.
84 Hoffman T, Wang, CY, Winchester RJ, Ferarrini M and Kunkel HG. Human lymphocyte bearing la-like antigens [now termed HLA-DR or class II MHC antigen]: Absence in patients with infantile Hypogammaglobulinemia. J immunol 1977; 119:1250.
85 Winchester RJ, Ross, GD, Jarowski CI, Wang, CY, Halper J and Broxmeyer HE. Expression of a la-like antigen on human granulocytes during early stages of differentiation. Proc Natl Acad Sci USA 1977; 74:4012.